Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
Evaluation of Serum and Ocular Coherence Tomography Biomarkers in Patients With Diabetic Macular Edema Treated With Anti-VEGF or Dexamethasone Implant
Vastra Gotaland Region
150 participants
Aug 1, 2025
INTERVENTIONAL
Conditions
Summary
This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these with a group of naive patients (those not previously treated for DME).
Eligibility
Inclusion Criteria2
- Type I or type II DM.
- DME involving the center of the fovea with CFT more than 280 microns and the presence of intraretinal cysts.
Exclusion Criteria7
- Prior history of any other macular disease.
- Previous treatment with dexamethasone implants in the last six months for those in the anti-VEGF group.
- Previous treatment with anti-VEGF in the last two months for those in the dexamethasone implant group.
- Prior vitreoretinal surgery.
- Previous laser treatment of the macula.
- Previous panretinal photocoagulation.
- Ocular surgery in the previous 3 months.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Treatment with intravitreal anti-VEGF treatment
Treatment with Dexamethasone implant
Treatment with intravitreal anti-VEGF OR treatment with Dexamethasone implant
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06984822